- Home
- ELWS vs KZIA Comparison
ELWS vs KZIA Comparison
Compare ELWS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELWS
- KZIA
- Stock Information
- Founded
- ELWS 2018
- KZIA 1994
- Country
- ELWS Japan
- KZIA Australia
- Employees
- ELWS N/A
- KZIA N/A
- Industry
- ELWS
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- ELWS
- KZIA Health Care
- Exchange
- ELWS Nasdaq
- KZIA Nasdaq
- Market Cap
- ELWS 6.2M
- KZIA 6.0M
- IPO Year
- ELWS 2023
- KZIA 1999
- Fundamental
- Price
- ELWS $2.15
- KZIA $0.80
- Analyst Decision
- ELWS
- KZIA Strong Buy
- Analyst Count
- ELWS 0
- KZIA 2
- Target Price
- ELWS N/A
- KZIA $11.50
- AVG Volume (30 Days)
- ELWS 12.5K
- KZIA 334.9K
- Earning Date
- ELWS 03-03-2025
- KZIA 04-11-2025
- Dividend Yield
- ELWS N/A
- KZIA N/A
- EPS Growth
- ELWS N/A
- KZIA N/A
- EPS
- ELWS N/A
- KZIA N/A
- Revenue
- ELWS $2,292,406.00
- KZIA $1,655,324.00
- Revenue This Year
- ELWS N/A
- KZIA N/A
- Revenue Next Year
- ELWS N/A
- KZIA N/A
- P/E Ratio
- ELWS N/A
- KZIA N/A
- Revenue Growth
- ELWS 404.13
- KZIA 248000.00
- 52 Week Low
- ELWS $1.04
- KZIA $0.76
- 52 Week High
- ELWS $8.68
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- ELWS 44.92
- KZIA 37.02
- Support Level
- ELWS $2.01
- KZIA $0.91
- Resistance Level
- ELWS $2.39
- KZIA $1.05
- Average True Range (ATR)
- ELWS 0.25
- KZIA 0.08
- MACD
- ELWS 0.05
- KZIA -0.00
- Stochastic Oscillator
- ELWS 43.73
- KZIA 12.34
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.